Results 1 to 10 of about 252,344 (145)

Dopamine Receptors: Is It Possible to Become a Therapeutic Target for Depression?

Frontiers in Pharmacology, 2022
Dopamine and its receptors are currently recognized targets for the treatment of several neuropsychiatric disorders, including Parkinson’s disease, schizophrenia, some drug use addictions, as well as depression.
Fangyi Zhao, Fangyi Zhao, Ziqian Cheng, Ziqian Cheng, Jingjing Piao, Jingjing Piao, Ranji Cui, Ranji Cui, Bingjin Li, Bingjin Li   +9 more
doaj   +1 more source

The Genetic Underpinnings of Affective Temperaments: Identifying Novel Risk Variants with a Whole Genome Analytical Approach

European Psychiatry, 2022
One reason behind the failure to understand the neurobiological background of affective disorders and develop more effective treatments is their heterogeneity warranting identification of clinically meaningful endophenotypes.
X. Gonda, N. Eszlari, D. Torok, Z. Gal, A. Millinghoffer, P. Antal, G. Juhasz, G. Bagdy   +7 more
doaj   +1 more source

Association of genetic variants of Glutamate Metabotropic Receptor 5 gene and state-anhedonia

European Psychiatry, 2022
Introduction Andedonia is one of the core symptoms of depression. It is known that in case of depressed individuals experiencing anhedonia, the classical antidepressants are often ineffective, thus investigation of this symptom would be essential ...
D. Török, X. Gonda, Z. Gal, N. Eszlari, G. Bagdy, G. Juhasz, P. Petschner   +6 more
doaj   +1 more source

Genetic underpinnings of affective temperaments: a pilot GWAS investigation identifies a new genome-wide significant SNP for anxious temperament in ADGRB3 gene

Translational Psychiatry, 2021
Although recently a large-sample GWASs identified significant loci in the background of depression, the heterogeneity of the depressive phenotype and the lack of accurate phenotyping hinders applicability of findings.
Xenia Gonda, Nora Eszlari, Dora Torok, Zsofia Gal, Janos Bokor, Andras Millinghoffer, Daniel Baksa, Peter Petschner, Peter Antal, Gerome Breen, Gabriella Juhasz, Gyorgy Bagdy   +11 more
doaj   +1 more source

Epigenetic Mechanism of Early Life Stress-Induced Depression: Focus on the Neurotransmitter Systems

Frontiers in Cell and Developmental Biology, 2022
Depression has an alarmingly high prevalence worldwide. A growing body of evidence indicates that environmental factors significantly affect the neural development and function of the central nervous system and then induce psychiatric disorders.
Ziqian Cheng, Ziqian Cheng, Jingyun Su, Jingyun Su, Kai Zhang, Huiyi Jiang, Bingjin Li, Bingjin Li   +7 more
doaj   +1 more source

Improvement of hedonic perception of odors as a marker of treatment response to escitalopram: olfactory changes through an open-label antidepressant trial [PDF]

Brazilian Journal of Psychiatry, 2023
Objectives: To assess olfactory functions (threshold, identification, and hedonic valence) of depressed subjects before and after an 8-week trial of escitalopram and compare the results of responders and nonresponders.
François Kazour, Boriana Atanasova, Thomas Desmidt, Valérie Gissot, Apolline Lefevre, Vincent Camus, Catherine Belzung, Wissam El-Hage   +7 more
doaj   +1 more source

Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer’s disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea

Frontiers in Aging Neuroscience, 2023
BackgroundVortioxetine has demonstrated procognitive effects in patients with major depressive disorder (MDD). We assessed the effectiveness and safety of vortioxetine in a cohort of patients with MDD and comorbid Alzheimer’s disease participating in a ...
Eduardo Cumbo, Michael Adair, Daniel Oudin Åstrom, Michael Cronquist Christensen   +3 more
doaj   +1 more source

Experimental pharmacological research regarding the antidepressant effect of associating doxepin and selegiline in normal mice [PDF]

, 2019
The severity and complexity of depression can vary widely among individuals, thus making single drug therapy ineffective in some cases. Taking this fact into account and using a mouse model, we set on investigating the possibility of obtaining a ...
Chiriță, Cornel, Dănciulescu Miulescu, Rucsandra E, Limban, Carmen, Marineci, Cristina D, Mireșan, Horațiu, Negreș, Simona, Nuță, Diana C, Zbârcea, Cristina E, Ștefănescu, Emil   +8 more
core   +2 more sources

Antidepressant Use and Depressive Symptoms in Intensive Care Unit Survivors [PDF]

, 2017
Nearly 30% of intensive care unit (ICU) survivors have depressive symptoms 2-12 months after hospital discharge. We examined the prevalence of depressive symptoms and risk factors for depressive symptoms in 204 patients at their initial evaluation in the
Boustani, Malaz, Gao, Sujuan, Khan, Babar, Khan, Sikandar, Kheir, You Na, Kirk, Kayla, Lasiter, Sue, Mosher, Chris, Wang, Sophia   +8 more
core   +1 more source

Fluoxetine: a case history of its discovery and preclinical development [PDF]

, 2014
Introduction: Depression is a multifactorial mood disorder with a high prevalence worldwide. Until now, treatments for depression have focused on the inhibition of monoaminergic reuptake sites, which augment the bioavailability of monoamines in the CNS ...
Bel N, Bergstrom RF, Bravo L, Bremner JD, Burrows GD, Chouinard G, Datla KP, Esther Berrocoso, Juan Antonio Mico, Kreiss DS, Laura Perez-Caballero, Lemberger L, Li Q, Lidia Bravo, Maj J, Nibuya M, Owens MJ, Rutter JJ, Sonia Torres-Sanchez, Stevens JC, Wong DT   +20 more
core   +2 more sources